# PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

> **NCT05852873** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Haukeland University Hospital** · enrollment: 2000 (estimated)

## Conditions studied

- Post COVID-19 Condition, Unspecified
- SARS-CoV2 Infection
- COVID-19

## Interventions

- **DRUG:** Nirmatrelvir/ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05852873
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-12
- **Primary completion:** 2025-09-09
- **Final completion:** 2027-06-11
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05852873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05852873, "PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05852873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*